BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $28.00 at Citizens Jmp

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price raised by Citizens Jmp from $25.00 to $28.00 in a research note released on Thursday,Benzinga reports. Citizens Jmp currently has a market outperform rating on the biotechnology company’s stock.

BCRX has been the subject of a number of other reports. Evercore initiated coverage on BioCryst Pharmaceuticals in a research note on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price objective for the company. Needham & Company LLC reduced their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday. Royal Bank Of Canada decreased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Wedbush reduced their price target on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, Weiss Ratings raised shares of BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Wednesday, March 4th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.70.

BioCryst Pharmaceuticals Stock Down 2.2%

BCRX traded down $0.20 during trading on Thursday, hitting $8.71. The company’s stock had a trading volume of 2,435,231 shares, compared to its average volume of 5,075,534. The firm’s 50 day moving average price is $9.08 and its two-hundred day moving average price is $7.83. The stock has a market capitalization of $2.21 billion, a price-to-earnings ratio of -4.91 and a beta of 0.57. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The firm had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 91.42%. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.20 earnings per share. On average, sell-side analysts forecast that BioCryst Pharmaceuticals will post 0.26 earnings per share for the current year.

Insider Transactions at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 150,000 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $9.15, for a total value of $1,372,500.00. Following the transaction, the insider owned 400,703 shares of the company’s stock, valued at approximately $3,666,432.45. This represents a 27.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in BCRX. Larson Financial Group LLC lifted its stake in shares of BioCryst Pharmaceuticals by 1,188.0% in the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 3,267 shares during the last quarter. Focus Partners Wealth bought a new position in BioCryst Pharmaceuticals during the third quarter worth $77,000. Farther Finance Advisors LLC boosted its position in shares of BioCryst Pharmaceuticals by 326.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 8,109 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 2,115 shares in the last quarter. Finally, Vestmark Advisory Solutions Inc. bought a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at $81,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.